Deal Details
Nurix Completes $250.0 Million Follow-On Offering
Summary
Nurix Therapeutics, Inc. (“Nurix”) (NASDAQ: NRIX) recently announced an underwritten registered offering of 24,485,799 shares of its common stock at a price of $10.21 per share, generating gross proceeds of $250.0 million. Nurix intends to use net proceeds from the offering primarily to fund clinical development of its drug candidates, including the clinical development of bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL) and for the exploration of potential autoimmune indications, to fund research and development activities to expand its pipeline and for working capital and general corporate purposes.
The offering includes participation from both new and existing investors including General Atlantic, Redmile Group, Braidwell LP, Deep Track Capital, Perceptive Advisors, Trails Edge Capital Partners and Vestal Point Capital, as well as other healthcare-dedicated funds.
Baird acted as a lead manager for the offering.
About
Nurix is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California.- Date
- October 2025
- Company
- Nurix Therapeutics, Inc.
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share
